<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102724</url>
  </required_header>
  <id_info>
    <org_study_id>5P20MD006886</org_study_id>
    <nct_id>NCT02102724</nct_id>
  </id_info>
  <brief_title>Fish Oil for HIV-Related Inflamm-aging and Immune Senescence</brief_title>
  <official_title>Fish Oil for HIV-Related Inflamm-aging and Immune Senescence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV infection is associated with premature aging of the immune system. It is believe that the&#xD;
      persistent inflammation that accompanies HIV infection is a major contributor to premature&#xD;
      immune aging. Fish oil has well-documented anti-inflammatory properties. In this randomized,&#xD;
      clinical trial, we're testing whether a 12-week course of fish oil supplementation will&#xD;
      reverse premature aging in HIV-infected older adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to treatment advances, the number of persons &gt; 50 years old who are living with HIV/AIDS&#xD;
      in the United States (US) has steadily increased. African Americans (AA) represent a&#xD;
      disproportionate number of HIV/AIDS cases in this age group, with infection rates 12 times&#xD;
      higher than among whites (51.7 per 100,000 compared to 4.2 per 100,000). Limited data suggest&#xD;
      that older HIV+ AA are characterized by health status disparities. One cohort study of older,&#xD;
      largely minority HIV+ persons (N=121, AA=83%;mean age=54), found that 34% had metabolic&#xD;
      syndrome and 50% had a Framingham Cardiac Risk score &gt; 10%. HIV+ older adults of all races&#xD;
      show a premature onset of other age-associated co-morbidities, such as osteoporosis, non-AIDS&#xD;
      malignancies, and cardiovascular disease (CVD). These co-morbidities have been linked to&#xD;
      persistent inflammation and persistently elevated serum levels of proinflammatory cytokines&#xD;
      that mimic an aging phenotype known as &quot;inflamm-aging.&quot; In both middle-aged HIV+ persons and&#xD;
      older HIV seronegative adults, inflamm-aging is associated with more limited T cell&#xD;
      repertoires and increased risk for morbidities and mortality. In HIV infection, inflamm-aging&#xD;
      is postulated to be maintained (a) by the constant antigen burden imposed by HIV and other&#xD;
      chronic viral co-pathogens, such as cytomegalovirus (CMV), and (b) by HIV-induced disruption&#xD;
      of intestinal epithelial integrity with subsequent translocation of gut microflora into the&#xD;
      systemic circulation. Our hypothesis is that inflamm-aging is responsible for the premature&#xD;
      immune senescence associated with HIV infection in aging individuals. Immune senescence,&#xD;
      characterized by diminished replicative capacity, has been observed in middle-aged persons&#xD;
      treated with highly active antiretroviral therapy (HAART) who achieve immune reconstitution&#xD;
      and undetectable viral loads. Senescent cells are characterized by the absence of the surface&#xD;
      marker CD28, and in advanced senescence express CD57 (CD28-/CD57+ phenotype). Because&#xD;
      premature senescence leads to loss of anti-HIV cell-mediated immune responses and accelerated&#xD;
      HIV disease progression,there is an urgent need to test new treatment strategies to reduce&#xD;
      inflamm-aging and subsequent immune senescence.&#xD;
&#xD;
      Fish oil may be an effective treatment option for reducing HIV-related inflamm-aging. Cold&#xD;
      water fish are rich in the omega-3 highly unsaturated fatty acids (HUFA) eicosapentaenoic&#xD;
      acid (EPA) and docosahexaenoic acid (DHA), which have anti-inflammatory effects. When&#xD;
      consumed as fish or fish oil supplements, EPA and DHA replace arachidonic acid in cell&#xD;
      membranes and inhibit the synthesis of proinflammatory arachidonic acid metabolites, such as&#xD;
      prostaglandins and leukotrienes. Moreover, animal and in vitro studies have shown that EPA&#xD;
      and DHA stimulate regeneration of intestinal mucosa damaged by methotrexate,16 IL-4, and&#xD;
      experimental ulcerative colitis. Yet, to date, no studies have been conducted on the effects&#xD;
      of fish oil for reducing HIV-related inflamm-aging and reversing immune senescence.&#xD;
&#xD;
      The purpose of this study is to explore the safety and estimate the effect size of fish oil&#xD;
      to modulate parameters of inflamm-aging and immune senescence in HIV+ older adults.&#xD;
      Participants will receive either 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA,&#xD;
      200 mg other omega-3 fatty acids) or placebo for 12 weeks. We expect to find a reduction in&#xD;
      inflammatory markers and the percentage of CD8+ and CD4+ T lymphocytes that exhibit a&#xD;
      senescent phenotype in the fish oil condition, but not in the control condition, at 12 weeks.&#xD;
      We expect to find no difference between the conditions on the safety parameters at 4 and 12&#xD;
      weeks.&#xD;
&#xD;
      The specific aims are:&#xD;
&#xD;
      Aim 1. To assess the safety of the fish oil condition by comparing it to the control&#xD;
      condition at 4 and 12 weeks, controlling for covariates (demographics, lifestyle, medications&#xD;
      including HAART, fish oil supplement adherence, intercurrent illnesses), on&#xD;
&#xD;
        1. HIV disease parameters (CD4+ T cell counts and HIV RNA levels)&#xD;
&#xD;
        2. Drug toxicity (liver function tests and serum creatinine)&#xD;
&#xD;
        3. Adverse events (e.g., diarrhea, vomiting)&#xD;
&#xD;
      Aim 2. To estimate the effect size of the fish oil condition at 12 weeks, controlling for&#xD;
      covariates, by comparing the following cell surface molecules and intracellular and soluble&#xD;
      inflammatory markers before and after fish oil&#xD;
&#xD;
        1. Markers of immune senescence on CD8+ T lymphocytes: percentage of CD8+/CD28- T&#xD;
           lymphocytes, a phenotype of immune senescence (primary outcome); percentage of&#xD;
           CD8+/CD28-/CD57- T lymphocytes (an intermediate senescent phenotype); percentage of&#xD;
           CD8+/CD28-/CD57+ T lymphocytes (a terminally differentiated senescent phenotype)&#xD;
&#xD;
        2. Markers of immune senescence on CD4+ T lymphocytes: percentage of CD4+/CD28- T&#xD;
           lymphocytes; percentage of CD4+/CD28-/CD57- T lymphocytes; percentage of&#xD;
           CD4+/CD28-/CD57+ T lymphocytes&#xD;
&#xD;
        3. Markers of inflammation: plasma hsCRP and intracellular concentrations of TNF-alpha,&#xD;
           IL-6, and gamma IFN&#xD;
&#xD;
      Aim 3: To estimate the effect size of the fish oil condition at 12 weeks on gut permeability,&#xD;
      controlling for covariates, by comparing the following indirect markers of gut permeability&#xD;
      before and after fish oil&#xD;
&#xD;
        1. Endotoxin&#xD;
&#xD;
        2. Soluble mouse CD14&#xD;
&#xD;
        3. Endotoxin binding antibody&#xD;
&#xD;
        4. Lipopolysaccharide binding protein&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants were randomized to one of two arms:&#xD;
Intervention arm = fish oil Control arm = placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All gelcaps were overencapsulated to mask their contents</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation</measure>
    <time_frame>End of 12-Week Supplementation Period</time_frame>
    <description>Markers of immune senescence will include change in the expression of the senescence markers CD28 and CD57 on the surface of peripheral CD4+ and CD8+ T lymphocytes. We will measure the percentage of CD4+ and CD8+ T lymphocytes that are CD28-/CD57- or CD28-/CD57+. We will subtract the percentage obtained at Week 12 from the baseline percentage to calculate the change scores.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 1 gram of oleic sunflower oil for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil that contains omega-3 fatty acids</intervention_name>
    <description>Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <other_name>Carlson Brand fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gelcaps that contain 1 gram of oleic sunflower oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  documented HIV infection&#xD;
&#xD;
          -  between 40 and 70 years of age&#xD;
&#xD;
          -  clinically stable HIV disease as evidenced by a CD4+ T lymphocyte count of &gt; 250&#xD;
             cells/mm3&#xD;
&#xD;
          -  platelet count between 150,000 and 400,000 cells/mm3 to reduce bleeding risks&#xD;
             associated with omega 3-fatty acids&#xD;
&#xD;
          -  treatment with a stable HAART regimen for at least six months prior to study entry&#xD;
&#xD;
          -  plasma HIV RNA &lt; 75 copies/ml for at least 12 months&#xD;
&#xD;
          -  elevated plasma concentration of hsCRP (&gt; 2.0 mg/L).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use within the past month of drugs (e.g., statins, steroids, hormones) and supplements&#xD;
             (e.g., omega-3 fatty acids, glucosamine/chondroitin) that have anti-inflammatory&#xD;
             effects (excluding non-regular use of aspirin or NSAIDS), or medications or&#xD;
             supplements that affect bleeding (e.g., heparin, warfarin, clopidogrel, garlic,&#xD;
             ginseng)&#xD;
&#xD;
          -  allergy to fish or shellfish&#xD;
&#xD;
          -  chronic inflammatory condition (e.g., asthma, rheumatoid arthritis), opportunistic&#xD;
             infection or cancer, renal impairment (serum creatinine &gt; 2.0 mg/dL), thrombocytopenia&#xD;
             (platelet count &lt; 150,000/mm3), bleeding episodes (e.g., gum bleeding, nosebleeds), or&#xD;
             a metabolic condition (e.g., diabetes mellitus, thyroid disease)&#xD;
&#xD;
          -  body mass index of &gt; 35, since obesity is associated with inflammation&#xD;
&#xD;
          -  impaired liver function as evidenced by liver enzyme elevations &gt; three times the&#xD;
             upper limit of normal (AST or ALT &gt; 150 IU/L)&#xD;
&#xD;
          -  history of prostate cancer&#xD;
&#xD;
          -  LDL cholesterol level &gt; 120 mg/dL&#xD;
&#xD;
          -  lifestyle exclusion factors include use of illicit drugs and consumption of &gt; 3&#xD;
             alcoholic drinks/day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara A. Swanson, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University College of Nursing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <results_first_submitted>August 13, 2018</results_first_submitted>
  <results_first_submitted_qc>March 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>African Americans</keyword>
  <keyword>Older Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fish Oil</title>
          <description>Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive 1 gram of oleic sunflower oil for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>surgery for brain aneurysm</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fish Oil</title>
          <description>Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive 1 gram of oleic sunflower oil for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="5.4"/>
                    <measurement group_id="B2" value="53" spread="6.1"/>
                    <measurement group_id="B3" value="54" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation</title>
        <description>Markers of immune senescence will include change in the expression of the senescence markers CD28 and CD57 on the surface of peripheral CD4+ and CD8+ T lymphocytes. We will measure the percentage of CD4+ and CD8+ T lymphocytes that are CD28-/CD57- or CD28-/CD57+. We will subtract the percentage obtained at Week 12 from the baseline percentage to calculate the change scores.</description>
        <time_frame>End of 12-Week Supplementation Period</time_frame>
        <population>Wilcoxon rank sum tests for intergroup change scores</population>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive 1 gram of oleic sunflower oil for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation</title>
          <description>Markers of immune senescence will include change in the expression of the senescence markers CD28 and CD57 on the surface of peripheral CD4+ and CD8+ T lymphocytes. We will measure the percentage of CD4+ and CD8+ T lymphocytes that are CD28-/CD57- or CD28-/CD57+. We will subtract the percentage obtained at Week 12 from the baseline percentage to calculate the change scores.</description>
          <population>Wilcoxon rank sum tests for intergroup change scores</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent CD4+ cells CD28+/CD57-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="-2.8" upper_limit="6.5"/>
                    <measurement group_id="O2" value="4.22" lower_limit="-3.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent CD4+ cells CD28-/CD57-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" lower_limit="-6.9" upper_limit="1.2"/>
                    <measurement group_id="O2" value="-1.56" lower_limit="-3.0" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent CD4+ cells CD28-/CD57+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="-1.2" upper_limit="2.5"/>
                    <measurement group_id="O2" value="-2.41" lower_limit="-9.6" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent CD8+ cells CD28+/CD57-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" lower_limit="-10.8" upper_limit="7.7"/>
                    <measurement group_id="O2" value="-4.63" lower_limit="-19.6" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent CD8+ cells CD28-/CD57-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-7.7" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.79" lower_limit="-4.8" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent CD8+ cells CD28-/CD57+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" lower_limit="-8.7" upper_limit="4.4"/>
                    <measurement group_id="O2" value="1.96" lower_limit="-6.2" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypotheses were that there are no differences between the two groups' change scores for any study outcomes. The power analysis was based on a study of krill oil for reducing CRP levels in persons with arthritis (N = 90) that yielded an effect size (Cohen's d) of 1.2. A sample size of 37 was determined to yield a power of 0.80 to detect an effect size of 1.0 with a two-tailed alpha of 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <other_analysis_desc>The change scores of the two groups (week 12 minus baseline) were compared using Wilcoxon rank sum tests.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over the 12-week supplementation period</time_frame>
      <desc>Adverse event data were collected at baseline, week four and week 12.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fish Oil</title>
          <description>Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive 1 gram of oleic sunflower oil for 12 weeks.&#xD;
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>brain aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI disturbance</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size; only single dose tested; duration may be too short to detect effects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Barbara Swanson</name_or_title>
      <organization>Rush University College of Nursing</organization>
      <phone>3129428977</phone>
      <email>BARBARA_A_SWANSON@RUSH.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

